Skip to main content
SupplementScience
Serrapeptase supplement
Proteolytic Enzyme

Serrapeptase: Benefits, Dosage, Forms & Research

Proteolytic Enzyme

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

TL;DR — Quick Answer

Serrapeptase at 10-60mg (60,000-120,000 SPU) daily may reduce post-surgical swelling, sinusitis symptoms, and inflammatory pain. It works by degrading fibrin and inflammatory proteins. Evidence is emerging — take on an empty stomach for systemic absorption.

Key Facts

What it is
A proteolytic enzyme from Serratia marcescens that degrades fibrin and inflammatory proteins
Primary benefits
  • Reduces post-surgical and traumatic swelling
  • Degrades fibrin and scar tissue
  • May improve sinusitis symptoms
  • Anti-edema and mucolytic properties
Typical dosage
10-60mg daily (60,000-120,000 SPU)
Evidence level
Emerging
Safety profile
Generally Safe

What the Research Says

Serrapeptase has been used clinically in Japan and Europe since the 1970s, primarily for post-surgical swelling and ENT conditions. The evidence base includes several small-to-moderate RCTs. Al-Khateeb and Nusair (2008) confirmed benefit for post-dental-surgery swelling. Mazzone et al. (1990) demonstrated significant improvements in chronic sinusitis symptoms. However, a 2017 systematic review (Bhagat et al.) noted that many studies are older, have small sample sizes, and variable methodology. The enzyme is absorbed intact from the GI tract when enteric-coated, reaching measurable serum levels. Its unique mechanism — degrading non-living protein debris while sparing living tissue — makes it theoretically useful for inflammation, but larger modern RCTs are needed to establish definitive efficacy.

Benefits of Serrapeptase

  • Post-surgical swelling — Al-Khateeb and Nusair (2008, n=24) found serrapeptase significantly reduced facial swelling and pain intensity after third molar extraction compared to placebo
  • Fibrinolytic activity — serrapeptase degrades fibrin, reducing blood clot formation and tissue adhesions at sites of inflammation and surgical wounds
  • Sinusitis — Mazzone et al. (1990, n=193) found serrapeptase significantly improved nasal obstruction, rhinorrhea, and facial pain in chronic sinusitis patients
  • Carpal tunnel syndrome — a pilot study (Panagariya and Sharma, 1999) found serrapeptase improved clinical symptoms in 65% of carpal tunnel patients over 6 weeks
  • Mucolytic effects — serrapeptase reduces mucus viscosity by cleaving glycoproteins, improving drainage in sinusitis and bronchitis
Did you know?

Serrapeptase has been used clinically in Japan and Europe since the 1970s, primarily for post-surgical swelling and ENT conditions.

Forms of Serrapeptase

FormBioavailabilityBest For
Enteric-Coated TabletsHighSystemic use — enteric coating protects enzyme from stomach acid destruction
Delayed-Release CapsulesHighAlternative to enteric coating — releases in small intestine for systemic absorption
Standard CapsulesLowNot recommended — enzyme is largely destroyed by stomach acid without enteric protection

Dosage Recommendations

General recommendation: 10-60mg daily (60,000-120,000 SPU), taken on an empty stomach with enteric-coated formulation

Timing: Take on an empty stomach (30 min before or 2 hours after meals) for systemic enzyme absorption

Dosage by Condition

ConditionRecommended DoseEvidence
Post-surgical swelling10-30mg (60,000 SPU) three times daily for 7 daysEmerging
Sinusitis30mg (60,000 SPU) dailyEmerging
General anti-inflammatory10-30mg dailyPreliminary

Upper limit: Up to 60mg daily has been used in clinical studies without significant adverse effects

Side Effects and Safety

Safety profile: Generally Safe

Potential Side Effects

  • Gastrointestinal discomfort (nausea, diarrhea) — uncommon with enteric-coated forms
  • Skin reactions (dermatitis, itching) — rare
  • Potential increased bleeding risk due to fibrinolytic activity
  • Rare case reports of pneumonitis with long-term use

Drug & Supplement Interactions

  • Anticoagulants (warfarin, aspirin, heparin) — serrapeptase has fibrinolytic activity; may increase bleeding risk
  • Antibiotics — serrapeptase may increase tissue penetration of antibiotics (potentially beneficial interaction)
  • NSAIDs — additive anti-inflammatory effects; may allow dose reduction under supervision
Check Serrapeptase interactions with other supplements →
BenefitsDosage GuideSide EffectsTypes & FormsResearchFAQ

Related Conditions

Inflammation

Related Supplements

BromelainTurmeric / CurcuminBoswellia

Frequently Asked Questions

What does SPU mean on serrapeptase labels?

SPU (Serratiopeptidase Units) measures the enzyme's proteolytic activity. A typical dose is 60,000-120,000 SPU (equivalent to 10-60mg). Some products use SU (Serrapeptase Units). Always compare enzymatic activity units, not just milligrams, when choosing products.

Why must serrapeptase be enteric-coated?

Serrapeptase is a protein enzyme that is destroyed by stomach acid. Enteric coating protects it until it reaches the alkaline environment of the small intestine, where it is absorbed intact into the bloodstream. Without enteric coating, most of the enzyme is inactivated before absorption.

How does serrapeptase compare to bromelain?

Both are proteolytic enzymes used for inflammation. Serrapeptase has stronger fibrinolytic (clot-dissolving) activity, while bromelain has broader clinical evidence and COX-modulating effects. Some practitioners combine them. Bromelain has a larger evidence base, but serrapeptase may be superior for fibrin-related conditions.

References

  1. (). Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral and Maxillofacial Surgery. DOI
  2. (). Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology. Journal of International Medical Research. DOI
  3. (). Serratiopeptidase: a systematic review of the existing evidence. International Journal of Surgery. DOI